Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Anheuser-Busch Inbev SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while Anheuser-Busch Inbev SA trades at $79.14 (market cap $153.32B). The key difference: Anheuser-Busch Inbev SA is far larger — about 3.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Anheuser-Busch Inbev SA pays a 1.69% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BUD | |
|---|---|---|
Market Cap | $39.89B | $153.32B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $85.09 |
52-Week Low | $278.09 | $57.10 |
Enterprise Value | $38.15B | $214.50B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BUD trades at $79.61, up 0.34% on the day, with a bearish technical signal despite recent earnings beats. The company shows stable revenue near $59B and improving net margins, now at 11.9%. Analyst consensus is bullish with a $90.08 price target, supported by dividend payments and strategic investments in premiumization and digital expansion.
Outlook remains positive due to strong fundamentals and analyst support, but risks include industry volume declines and competitive pressures. The stock offers value through dividends and potential upside to target, though technical weakness suggests near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
